News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AltheRx is Granted U.S. Patent for Use of Solabegron in Combination With Antimuscarinics for the Treatment of Overactive Bladder



10/17/2013 10:13:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company’s U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB). Upon issuance, the patent will provide AltheRx a strong position through the early 2030s.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
AltheRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES